Evolus, Inc. (NASDAQ:EOLS – Get Rating) Director Robert Hayman bought 1,091 shares of the firm's stock in a transaction on Monday, September 12th. The shares were acquired at an average price of $10.78 per share, for a total transaction of $11,760.98. Following the transaction, the director now owns 10,000 shares in the company, valued at $107,800. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Robert Hayman also recently made the following trade(s):
Get
Evolus alerts:
- On Friday, September 9th, Robert Hayman bought 8,909 shares of Evolus stock. The shares were acquired at an average price of $10.35 per share, for a total transaction of $92,208.15.
- On Wednesday, September 7th, Robert Hayman purchased 4,967 shares of Evolus stock. The shares were purchased at an average price of $10.05 per share, for a total transaction of $49,918.35.
Evolus Price Performance
Shares of NASDAQ:EOLS opened at $10.16 on Friday. The company has a market cap of $569.93 million, a price-to-earnings ratio of -7.21 and a beta of 2.01. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.60 and a quick ratio of 2.36. The firm has a 50 day simple moving average of $10.86 and a 200 day simple moving average of $11.30. Evolus, Inc. has a one year low of $5.06 and a one year high of $14.34.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC assumed coverage on shares of Evolus in a research report on Thursday, June 23rd. They set a "buy" rating and a $18.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $15.33.
Hedge Funds Weigh In On Evolus
Several institutional investors and hedge funds have recently added to or reduced their stakes in EOLS. Deerfield Management Company L.P. Series C lifted its stake in Evolus by 195.5% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,632,751 shares of the company's stock valued at $42,140,000 after purchasing an additional 2,403,517 shares during the last quarter. Stonepine Capital Management LLC lifted its stake in Evolus by 521.0% in the 4th quarter. Stonepine Capital Management LLC now owns 1,863,096 shares of the company's stock valued at $12,129,000 after purchasing an additional 1,563,096 shares during the last quarter. AIGH Capital Management LLC bought a new position in Evolus in the 1st quarter valued at approximately $10,249,000. First Manhattan Co. lifted its stake in Evolus by 22.5% in the 1st quarter. First Manhattan Co. now owns 4,084,938 shares of the company's stock valued at $45,833,000 after purchasing an additional 750,022 shares during the last quarter. Finally, Schroder Investment Management Group lifted its stake in Evolus by 37.8% in the 4th quarter. Schroder Investment Management Group now owns 2,317,281 shares of the company's stock valued at $15,085,000 after purchasing an additional 636,109 shares during the last quarter. Institutional investors own 50.60% of the company's stock.
About Evolus
(Get Rating)
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Articles
- Get a free copy of the StockNews.com research report on Evolus (EOLS)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It's a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
